Bartels A L, van Berckel B N M, Lubberink M, Luurtsema G, Lammertsma A A, Leenders K L
Department of Neurology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.
Parkinsonism Relat Disord. 2008 Aug;14(6):505-8. doi: 10.1016/j.parkreldis.2007.11.007. Epub 2008 Mar 5.
The cause of Parkinson's disease (PD) is unknown. Genetic susceptibility and exposure to environmental toxins contribute to specific neuronal loss in PD. Decreased blood-brain barrier (BBB) P-glycoprotein (P-gp) efflux function has been proposed as a possible causative link between toxin exposure and PD neurodegeneration. In the present study BBB P-gp function was investigated in vivo in 10 early stage PD patients and 8 healthy control subjects using (R)-[(11)C]-verapamil and PET. Cerebral volume of distribution (V(d)) of verapamil was used as measure of P-gp function. Both region of interest (ROI) analysis and voxel analysis using statistical parametric mapping (SPM) were performed to assess regional brain P-gp function. In addition, MDR1 genetic polymorphism was assessed. In the present study, a larger variation in V(d) of (R)-[(11)C]-verapamil was seen in the PD group as compared to the control group. However, decreased BBB P-gp function in early stage PD patients could not be confirmed.
帕金森病（PD）的病因尚不清楚。遗传易感性和接触环境毒素会导致PD中特定神经元的丧失。血脑屏障（BBB）P-糖蛋白（P-gp）外排功能降低被认为是毒素暴露与PD神经变性之间可能的因果联系。在本研究中，使用（R）-[（11）C]-维拉帕米和PET在10例早期PD患者和8名健康对照受试者体内研究了BBB P-gp功能。维拉帕米的脑分布容积（V（d））用作P-gp功能的指标。采用感兴趣区（ROI）分析和使用统计参数映射（SPM）的体素分析来评估局部脑P-gp功能。此外，还评估了MDR1基因多态性。在本研究中，与对照组相比，PD组中（R）-[（11）C]-维拉帕米的V（d）变化更大。然而，早期PD患者血脑屏障P-gp功能降低未能得到证实。
